- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05925452
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
July 5, 2023 updated by: GeneScience Pharmaceuticals Co., Ltd.
A Multicenter, Randomized, Open-label Phase IIb Clinical Study to Evaluate the Efficacy and Safety of GenaKumab in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
A multicenter, randomized, open-label Phase IIb clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jintao Yue
- Phone Number: +86 15333202381
- Email: yuejintao@gensci-china.com
Study Locations
-
-
Benjing
-
Beijing, Benjing, China, 100045
- Children's Hospital Affiliated to Capital Medical University
-
Contact:
- Caifeng Li, Doctor
- Phone Number: +86-10-59616316
- Email: caifeng_li@yeah.net
-
-
Chongqing
-
Chongqing, Chongqing, China, 400015
- Children's Hospital Affiliated to Chongqing Medical University
-
Contact:
- Xuemei Tang, Doctor
- Phone Number: +86-0731-85356314
- Email: tangxuemei2008@163.com
-
-
Hunan
-
Changsha, Hunan, China, 410323
- Hunan Children's Hospital
-
Contact:
- Zhihui Li, Doctor
- Phone Number: +86-023-68370205
- Email: Lizh0731@aliyun.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Children's Hospital Affiliated to Nanjing Medical University
-
Contact:
- Qihua Feng, Doctor
- Phone Number: +86-0521-80698511
- Email: fqhwmh@163.com
-
Suzhou, Jiangsu, China, 215002
- Children's Hospital of Soochow University
-
Contact:
- Cuihua Liu, Doctor
- Phone Number: +86- 0371-85515853
- Email: Lchlch123@126.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 201102
- Affiliated Pediatric Hospital of Fudan University
-
Contact:
- Li Sun, Doctor
- Phone Number: +86-021-64931990
- Email: lillysun@263.net
-
-
Shanxi
-
Xi'an, Shanxi, China, 710002
- Xi'an Children's Hospital
-
Contact:
- Xiaoqing Zuo, Doctor
- Phone Number: +86-029- 87692043
- Email: xa_lxq@163.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610073
- Chengdu Women and Children's Central Hospital
-
Contact:
- Wenjie Zheng, Doctor
- Phone Number: +86-0557-81732562
- Email: wzwjzheng@sina.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Children's Hospital, Zhejiang University School of Medicine
-
Contact:
- Meiping Lu, Doctor
- Phone Number: +86-0571- 81732562
- Email: meipinglu@126.com
-
Wenzhou, Zhejiang, China, 325099
- The Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Haiguo Yu, Doctor
- Phone Number: +86-025-8311750
- Email: yuhaiguo73@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and female patients, with the remaining before age 2 years old or more and & lt; 18 years old;
- 2001 ILAR classification criteria for the diagnosis of confirmed sJIA 2 or more months: onset age must & lt; At 16 years of age, symptoms included: ≥1 case of arthritis, accompanied by or prior to ≥2 weeks of recurrent fever, including remittenor fever for ≥3 consecutive days (maximum daily body temperature ≥39 ° C, body temperature falling below 37 ° C between 2 heat peaks), accompanied by at least one of the following symptoms: ① a transient, non-fixed erythematous rash; ② systemic lymph node enlargement; Swelling of the liver and/or spleen; ④ Serositis.
- Agree to use effective means of contraception throughout the study period and for 6 months after the end of treatment.
Exclusion Criteria:
- Pregnant or lactating female subjects
- A history of allergic reactions to investigational drugs or to molecules with similar structures; Those who cannot be given intramuscular injections;
- History of pericarditis, myocarditis, serositis, bacterial heart valve or endocarditis within 6 months before screening; Patients who had been diagnosed with MAS within 6 months prior to screening, or had relevant symptoms and signs at screening, and were suspected of having MAS as assessed by the investigators;
- There are other rheumatic diseases such as Kawasaki disease, polyarteritis nodosa and so on. History of autoinflammatory diseases such as familial Mediterranean fever, high IgD syndrome, NLRP3-related autoinflammatory diseases;
- Patients with a history of interstitial lung disease, pulmonary fibrosis, alveolar proteinosis, or pulmonary hypertension; Patients with a history of repeated invasive fungal infection; In the 7 days prior to randomization, there were infections that required control with systemic antigenic microbiotics (including antibacterial, antiviral, antifungal, etc.);
- Subjects with a history of TB exposure or suspected TB symptoms.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GenaKumab
15 subjects: GenaKumab 0.5mg/kg dose group and 4.0 mg/kg dose group, Subcutaneous injection, Q4w
|
GenaKumab 0.5mg/kg dose group : GenaKumab 0.5 mg/kg, Subcutaneous injection, Q4w, Dose adjustable, The maximum is 4.0 mg/kg; GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg fixed dose, Subcutaneous injection, Q4w
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with successful glucocorticoid reduction by the end of the treatment period
Time Frame: 24 Week
|
24 Week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 16, 2023
Primary Completion (Estimated)
July 26, 2024
Study Completion (Estimated)
October 22, 2024
Study Registration Dates
First Submitted
June 21, 2023
First Submitted That Met QC Criteria
June 21, 2023
First Posted (Actual)
June 29, 2023
Study Record Updates
Last Update Posted (Actual)
July 7, 2023
Last Update Submitted That Met QC Criteria
July 5, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GenSci048-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Active Systemic Juvenile Idiopathic Arthritis
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
ItalfarmacoCompletedActive Systemic | Onset Juvenile Idiopathic ArthritisRomania, Serbia
-
Bristol-Myers SquibbCompletedActive Polyarticular Juvenile Idiopathic ArthritisUnited States, Spain, Belgium, Italy, Argentina, Brazil, France, Germany, Mexico, Peru, Russian Federation, South Africa
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
NovartisCompletedArthritis, Juvenile RheumatoidItaly
-
Regeneron PharmaceuticalsCompletedSystemic Juvenile Idiopathic ArthritisUnited States
-
AbbVieRecruitingJuvenile Idiopathic ArthritisUnited States, Australia, Japan, Turkey, China, Spain, Italy
-
SanofiRegeneron PharmaceuticalsRecruitingJuvenile Idiopathic ArthritisArgentina, Bulgaria, Canada, Finland, France, Germany, Ireland, Italy, Russian Federation, Spain, United Kingdom
Clinical Trials on GenaKumab
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMalignant Solid TumorsChina
-
GeneScience Pharmaceuticals Co., Ltd.Affiliated Hospital of North Sichuan Medical CollegeRecruitingInterstitial Lung DiseaseChina
-
GeneScience Pharmaceuticals Co., Ltd.Peking Union Medical College HospitalUnknownJuvenile Idiopathic ArthritisChina
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Changhai Hospital and other collaboratorsActive, not recruiting
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Recruiting
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina